Compare CNTB & VECA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTB | VECA |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 131.3M |
| IPO Year | 2020 | 2026 |
| Metric | CNTB | VECA |
|---|---|---|
| Price | $2.44 | $9.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 437.6K | 2.8K |
| Earning Date | 08-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $9.91 |
| 52 Week High | $3.82 | $9.98 |
| Indicator | CNTB | VECA |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 33.33 |
| Support Level | $2.30 | N/A |
| Resistance Level | $2.68 | N/A |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 94.83 | 42.86 |
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Vernal Capital Acquisition Corp is a blank check company.